Category Archives: COVID-19

Area News, COVID-19, Health Care

COVID-19 Health Challenges Persist For Many

Leave a comment

Cognition and Swallowing Among the Common Challenges Persisting for Many Americans After COVID-19

Speech-Language Pathologists Can Help Patients Regain Health and Quality of Life, NRMC Expert Stresses During Better Hearing & Speech Month

With an estimated 10 to 30% of COVID-19 survivors experiencing “long-haul” symptoms including brain fog and swallowing difficulties, Nevada Regional Medical Center speech-language pathologist Andrea Wydick is encouraging the public to seek care from qualified experts who can help them regain their functioning and quality of life. Wydick is sharing this message in recognition of May being national Better Hearing & Speech Month (BHSM).

“The pandemic has posed so many challenges to us all as a society, but one of the persisting and most vexing ones right now is the daunting set of difficulties many people are having for months after contracting COVID-19,” said Wydick. “From brain fog, to difficulty eating and drinking, to speech and language problems, these can affect return to work, the ability to take care of one’s family, and overall recovery. Many people don’t know about the services of speech-language pathologists—professionals trained in these areas who can make a huge difference for these people. This is an important time for us to spread the word: Help is available.”

How They Help

Speech-language pathologists (SLPs) can help people with, or recovering from, COVID-19 who are having short- and longer-term difficulties in the following areas:

• Cognition

Many COVID-19 “long-haulers” are reporting persistent brain fog as a debilitating symptom after their bout with the virus. This can prevent a return to work and impact their ability to tend to family responsibilities. SLPs can work with individuals to improve their memory, attention, organization and planning, problem solving, learning, and social communication—such as re-learning conversational rules or understanding the intent behind a message or behind nonverbal cues. The focus is on the person’s specific challenges as well as regaining the skills that are most important to their daily life and priorities.

• Swallowing

People diagnosed with COVID-19 may experience swallowing problems that can put them at risk for choking or aspirating, which is when food goes into the lungs instead of the stomach. This may be the result of time spent on a ventilator, or it may be another side effect of the virus. SLPs use different types of tests to determine what happens when a person swallows and how the related muscles are working—helping a patient’s medical team, including the SLP, decide on the best course of action with the patient and their family. SLPs may recommend modified textures of food and drink for patients; therapy exercises to strengthen the tongue, lips, and muscles in the mouth and throat; and strategies to make eating and drinking safer, such as modifying the pace of chewing/eating, size of food, and more.

• Communication

People diagnosed with COVID-19 are also experiencing speech and language difficulties. Some, such as those who spent a significant amount of time on a ventilator or experienced low oxygen to the brain, may have muscle weakness or reduced coordination in the muscles of the face, lips, tongue, and throat—making it difficult to talk. Others, particularly those who experienced a COVID-related stroke, may experience a language disorder called aphasia—which makes it hard for someone to understand, speak, read, or write. SLPs work with patients through targeted therapy to improve their communication and understanding.

People who have severe speech and/or language difficulties may need to find other ways to answer questions or tell people what they want, such as through gesturing with their hands, pointing to letters or pictures on a paper or board, or using a computer. These are all forms of augmentative and alternative communication (AAC). SLPs help find the appropriate AAC method to meet an individual’s needs.

Where to Find Care

SLPs work in settings that include hospitals, long- and short-term care facilities, private practices, and patients’ homes. Many SLPs are also providing their services via telehealth at this time. If you or a loved one are experiencing communication challenges, Wydick recommends letting your doctor know.

For more information, Vernon County and area residents can contact NRMC Performance Therapy at 417-448-3790, or visit www.asha.org/public.

###

About Nevada Regional Medical Center
Serving a six-county area since 1937, Nevada Regional Medical Center is a 71-bed acute, intensive and skilled care hospital. Nevada Regional Medical Center has earned recognition as a respected regional medical center for its comprehensive health care services, skilled and caring employees and state-of-the-art medical technology. Staff represent more than a dozen medical specialties, including family practice, women’s services, neurology, urology, psychiatry, orthopedics, wound care services, and general, vascular, thoracic and oncological surgery. Additionally, consultation clinics are held regularly by specialists in oncology, pulmonology, podiatry, ear, nose, and throat and cardiology.

COVID-19, Government, Kansas

Restaurants: Apply For Revitalization Grants

Leave a comment

Governor Laura Kelly Encourages Kansas Restaurants Apply for Restaurant Revitalization Fund Grants

~Revitalization Fund Grants will boost hospitality industry and aid continued economic recovery~

TOPEKA – Governor Laura Kelly today urged Kansas restaurants and eligible businesses in the hospitality industry to apply for federal funding through the Small Business Administration’s (SBA) Restaurant Revitalization Fund (RRF). Registration for the RRF began on Friday, April 30, 2021, at 8 AM CT and applications will open on Monday, May 3, 2021, at 11 AM CT.

“These RRF grants will boost our hospitality industry and aid our continued economic recovery as we get our state back to normal,” said Governor Laura Kelly. “I strongly encourage all eligible businesses to apply for this program and thank the SBA for their partnership to provide relief for Kansas businesses.”

The SBA will be co-hosting a webinar for Kansas businesses with the Governor’s Office of Recovery, the Kansas Department of Commerce and the Kansas Department of Agriculture on Wednesday, May 5 at 9 AM CT. Learn more about the webinar at https://covid.ks.gov/rrf/.

“Restaurants are vital to our state’s hospitality sector, and this program exists solely to help them,” Lieutenant Governor and Commerce Secretary David Toland said. “Hospitality businesses have been incredibly resilient through this historic and unprecedented challenge, and restaurants have had to be creative to get through the storm. This program is a lifeline for them, and I would encourage all Kansas restaurant owners who need help to take full advantage.”

The American Rescue Plan Act established the Restaurant Revitalization Fund (RRF) to provide funding to help restaurants and other eligible businesses keep their doors open. This program will provide restaurants with funding equal to their pandemic-related revenue loss, up to $10 million per business and no more than $5 million per physical location. Recipients are not required to repay the funding as long as funds are used for eligible uses no later than March 11, 2023.

Entities eligible for the RRF include:

  • Restaurants;
  • Food stands, food trucks, food carts;
  • Caterers;
  • Bars, saloons, lounges, taverns;
  • Snack and nonalcoholic beverage bars;
  • Additional entities if onsite food or beverage sales are at least 33% of gross receipts (e.g. Bakeries, brewpubs, tasting rooms, taprooms, breweries and/or microbreweries, Wineries and distilleries, Inns).

“Restaurants and the food service industry are critical to the economic wellbeing of our communities,” said Michael Barrera, District Director, SBA-KC District. “Restaurants are gathering places for our cities and towns and are where many milestones and everyday conversations take place in our lives. The RRF will help keep these ‘centers of influence’ going and we here at the SBA look forward to working with our Kansas partners to make this program a Kansas success!”

“The RRF provides critical support to restaurants, food trucks, small caterers, coffee shops and other food service companies hit hard by the pandemic,” said Wayne Bell, District Director, SBA-Wichita District. “We want Kansas small businesses to be fully prepared for this opportunity.”

“As we look toward the future, it is crucial that we support the restaurant industry in every way we can,” said Ryan Wills, Kansas Department of Commerce Hospitality Industry Liaison. “Food service organizations provide nourishment to our community not just through food, but also through fellowship. They are essential to our economic vitality, and the Department of Commerce is looking forward to the RRF providing much needed relief to businesses across our great state.”

Learn more about the RRF and apply at https://www.sba.gov/funding-programs/loans/covid-19-relief-options/restaurant-revitalization-fund.

COVID-19

Kansas to Resume Johnson & Johnson Administration

Leave a comment

Kansas to Resume Johnson & Johnson Administration

TOPEKA – The Kansas Department of Health and Environment (KDHE) announces that Kansas will resume administration of the Johnson & Johnson (Janssen) COVID-19 vaccine following an announcement on April 23 from the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) encouraging resumption of the vaccine.

“Today, Kansas will resume administering the Johnson & Johnson COVID-19 vaccine,” said Governor Laura Kelly. “After a brief pause and a thorough review, the CDC and FDA have determined the vaccine is safe and effective. Whether it’s the Johnson and Johnson, Pfizer or Moderna, I strongly encourage every Kansan to get vaccinated as soon as they can.”

Johnson & Johnson administration was paused April 13 by the CDC and FDA following reports of recipients in the United States who developed a rare disorder involving blood clots within about two weeks of vaccination. During the pause, the FDA and CDC examined available data to assess the risk of the condition as well as conducted extensive outreach to providers and clinicians to ensure they were made aware of the potential for these adverse events and could properly manage and recognize these events due to the unique treatment required for these blood clots and low platelets, also known as thrombosis-thrombocytopenia syndrome (TTS). Following these reviews, the two agencies have recommended that Johnson & Johnson be resumed in the United States.

Kansas health care providers administering the Johnson & Johnson vaccine and vaccine recipients or caregivers should review the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Fact Sheet for Recipients and Caregivers, which have been revised to include information about the risk of this syndrome, which has occurred in a very small number of people who have received the Janssen COVID-19 Vaccine.

The federal government will continue studying links between the vaccine and the rare blood clotting disorder. Those who have received the Johnson & Johnson vaccine should contact their health care provider if they have any symptoms and report any illness to the VAERS Reporting System, https://vaers.hhs.gov.

Kansas’ next supply of Johnson & Johnson vaccine is anticipated the week of May 3 with 1,700 doses.

###

 

 

FDA and CDC April 23 Joint Statement:

 

Following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

The pause was recommended after reports of six cases of a rare and severe type of blood clot in individuals following administration of the Janssen COVID-19 Vaccine. During the pause, medical and scientific teams at the FDA and CDC examined available data to assess the risk of thrombosis involving the cerebral venous sinuses, or CVST (large blood vessels in the brain), and other sites in the body (including but not limited to the large blood vessels of the abdomen and the veins of the legs) along with thrombocytopenia, or low blood platelet counts. The teams at FDA and CDC also conducted extensive outreach to providers and clinicians to ensure they were made aware of the potential for these adverse events and could properly manage and recognize these events due to the unique treatment required for these blood clots and low platelets, also known as thrombosis-thrombocytopenia syndrome (TTS).

The two agencies have determined the following:

  • Use of the Janssen COVID-19 Vaccine should be resumed in the United States.
  • The FDA and CDC have confidence that this vaccine is safe and effective in preventing COVID-19.
  • The FDA has determined that the available data show that the vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.
  • At this time, the available data suggest that the chance of TTS occurring is very low, but the FDA and CDC will remain vigilant in continuing to investigate this risk.
  • Health care providers administering the vaccine and vaccine recipients or caregivers should review the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Fact Sheet for Recipients and Caregivers, which have been revised to include information about the risk of this syndrome, which has occurred in a very small number of people who have received the Janssen COVID-19 Vaccine.

CDC’s independent Advisory Committee on Immunization Practices met today to discuss the latest data on TTS, hearing from the vaccine manufacturer Janssen and the COVID-19 Vaccine Safety Technical (VaST) Subgroup, as well as a risk benefit analysis. ACIP is committed to be vigilant and responsive to additional information that could impact the risk benefit analysis of any of these vaccines. Vaccine safety monitoring will continue and any new information about TTS will be brought to ACIP as needed.

“Safety is our top priority. This pause was an example of our extensive safety monitoring working as they were designed to work—identifying even these small number of cases. We’ve lifted the pause based on the FDA and CDC’s review of all available data and in consultation with medical experts and based on recommendations from the CDC’s Advisory Committee on Immunization Practices. We have concluded that the known and potential benefits of the Janssen COVID-19 Vaccine outweigh its known and potential risks in individuals 18 years of age and older. We are confident that this vaccine continues to meet our standards for safety, effectiveness and quality. We recommend people with questions about which vaccine is right for them have those discussions with their health care provider,” said Janet Woodcock, M.D., Acting FDA Commissioner.

“Above all else, health and safety are at the forefront of our decisions,” said CDC Director Dr. Rochelle P. Walensky. “Our vaccine safety systems are working. We identified exceptionally rare events – out of millions of doses of the Janssen COVID-19 administered – and we paused to examine them more carefully. As we always do, we will continue to watch all signals closely as more Americans are vaccinated. I continue to be encouraged by the growing body of real-world evidence that the authorized COVID-19 vaccines are safe and effective, and they protect people from disease, hospitalization, and death. I urge anyone with questions about the COVID-19 vaccines to speak with their healthcare provider or local public health department.”

Assessment of Available Data

Medical and scientific teams at the FDA and CDC reviewed several sources of information and data related to the Janssen COVID-19 Vaccine to reach today’s decision.

Specifically, the agencies assessed reports submitted to the Vaccine Adverse Event Reporting System (VAERS), reviewed the medical literature and considered the information from global regulatory partners about thrombosis with thrombocytopenia that have been reported following use of a similar, yet not identical, COVID-19 vaccine using a virus from the adenovirus family that has been modified to contain the gene for making a protein from SARS-CoV-2.

Update on Adverse Events

On April 13, the FDA and CDC announced that, out of more than 6.8 million doses administered, six reports of a rare and severe type of blood clot combined with low blood platelet levels occurring in people after receiving the Janssen COVID-19 Vaccine had been reported to VAERS. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia).

Today, the agencies can confirm that a total of 15 cases of TTS have been reported to VAERS, including the original six reported cases. All of these cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Reports indicated symptom onset between 6 and 15 days after vaccination.

Monitoring for Safety Will Continue

The surveillance systems that are in place to monitor the safety of COVID-19 vaccines authorized for emergency use are working, as demonstrated by both agencies’ quick work to identify and investigate these rare, but serious adverse events. The FDA and CDC will continue with these efforts to closely monitor the safety of these vaccines.

Reports of adverse events following vaccination can be made to the Vaccine Adverse Event Reporting System.

COVID-19, Government, Kansas

KDHE amends travel quarantine list

Leave a comment

 

TOPEKA – The Kansas Department of Health and Environment (KDHE) has amended its travel quarantine list to add the state of Minnesota and the countries of Argentina, Aruba, Bahrain, Croatia, Cyprus, France, Sweden and Turkey.  The state of Connecticut and countries San Marino, Estonia and Jordan have been removed from the quarantine list.

A comprehensive list of those individuals needing to quarantine includes visitors and Kansans who have:

  • Traveled on or after April 22 to Minnesota or the countries of Argentina, Aruba, Bahrain, Croatia, Cyprus, France, Sweden and Turkey.
  • Traveled on or after April 8 to Pennsylvania or the countries of Andorra, Bermuda, Curacao, Poland, Serbia or Uruguay.
  • Traveled on or after March 26 to Delaware, Michigan or Rhode Island or the country of Hungary.
  • Traveled on or after March 12 to New Jersey or New York or the country of State of Palestine.
  • Traveled between April 8 – April 22 to Connecticut.
  • Traveled between March 26 – April 22 to Jordan.
  • Traveled between March 12 – April 22 to Estonia.
  • Traveled between Feb. 26 – April 22 to San Marino.
  • Attendance at any out-of-state mass gatherings of 500 or more where individuals do not socially distance (6 feet) and wear a mask.
  • Been on a cruise ship or river cruise on or after March 15, 2020.

The travel quarantine period is seven days with a negative test result or 10 days without testing, with release from quarantine on Day 8 and Day 11, respectively. Further information on quarantine periods can be found on KDHE’s website.

For those traveling internationally, the Centers for Disease Control and Prevention (CDC) is requiring testing within three days of flights into the U.S. For further information on this and other requirements, visit their website.

For those who are fully vaccinated (meaning it has been greater than two weeks since they completed their vaccinations) they are not required to quarantine regarding travel if they meet all of the following criteria:

  • Are fully vaccinated (i.e., ≥2 weeks following receipt of the second dose in a 2- dose series, or ≥2 weeks following receipt of one dose of a single-dose vaccine)
  • Are within 6 months following receipt of the last dose in the series
  • Have remained asymptomatic since the travel

Persons who do not meet all three of the above criteria should continue to follow current quarantine guidance for travel.

Additionally, people with previous COVID-19 disease are not required to quarantine following travel if they meet all of the following criteria:

  • Have evidence of a previous infection supported by a positive PCR or antigen test
  • Are within 6 months following infection. If an investigation was done documenting the date that symptoms resolved, or the date isolation measures were discontinued for asymptomatic patients, then the 6-month period can start from that end date. If those dates are not available, then the period will start from the date of the positive laboratory test. A serology or antibody test may not be substituted for a laboratory report of a viral diagnostic test.
  • Have remained asymptomatic since the travel

Persons who do not meet all three of the above criteria should continue to follow current quarantine guidance for travel.

The travel quarantine list is determined using a formula to evaluate new cases over a two-week period, then adjusted for population size to provide a case rate per 100,000 population. This provides a number that can then be compared to the rate in Kansas. Locations with significantly higher rates — approximately 3x higher — are added to the list.

For more information on COVID-19, please visit the KDHE website at www.kdhe.ks.gov/coronavirus.

Area News, COVID-19

CHC/SEK to host Pfizer vaccine clinic on April 25

Leave a comment
People aged 16 and older can now receive the Pfizer vaccine with parental consent through Community Health Center of Southeast Kansas.
CHC/SEK will host a Pfizer vaccine clinic from 8 a.m. to 1 p.m. on Sunday, April 25, at the 924 N Broadway. The clinic will be by appointment only. This is a two-dose vaccine that is given 21 days apart.
Individuals can request a vaccine appointment on the CHC/SEK website chcsek.org. Click the COVID Vaccine Request button. After selecting the “first dose” button, there is an option to select the Pfizer or Moderna vaccine. CHC/SEK representatives will contact the recipients to schedule a date for the vaccine.
For those without web access, the health center has a toll-free number, 866-888-8650 and a second number for Spanish-speakers 620-240-8940 to make vaccination appointments.

As with all COVID-19 vaccines, there is no out-of-pocket costs to vaccine recipients.

COVID-19, Government, Kansas

Bills Signed to Aid Economic Recovery

Leave a comment

Governor Laura Kelly Signs Bipartisan Legislation to Aid Kansas’s Economic Recovery

~Legislation prioritizes strategic growth, business recruitment, and innovation as the state recovers from COVID-19~

TOPEKA – Today, Governor Laura Kelly signed four bipartisan bills into law to drive economic growth and strengthen Kansas’ economy. Senate Bills 65, 66, 90, and 124 are part of Governor Kelly’s Growth Agenda, a multifaceted legislative approach to improving Kansas’ ability to attract major businesses and strengthen our economy in accordance with the Framework for Growth strategic plan.

“As our state recovers from COVID-19, we have the opportunity to rebuild a stronger, healthier, more resilient workforce and economy in Kansas,” said Governor Laura Kelly. “These bipartisan bills will help us achieve this goal by improving our ability to recruit cutting-edge businesses, revitalize our rural communities, and address housing shortages statewide. I thank the Legislature and Department of Commerce for their work on this important legislation.”

Each bill strengthens a specific area of Kansas economic development:

SB 65 – New improvements and updates to the High Performance Incentive Program (HPIP). Companies will no longer need to go through the Kansas Industrial Training/Retraining (KIT/KIR) programs to qualify for HPIP, leaving vital training funds to be used in more strategic ways. In addition, the bill allows for up to 50% of tax credits earned through HPIP to be transferred, helping to ensure that companies can fully utilize earned credits.

SB 66 – An extension of the Angel Investor Tax Credit program in Kansas for the next five years. Important updates have been made to the program, including changes to credit investment amounts, increasing budget appropriations and more. Strengthening the Angels program will allow our state to more effectively attract start-ups that will help create the technology of the future. In addition, an amendment to the bill provides for an increase in tax credits to be used to make homes accessible for people with disabilities.

SB 90 – This bill significantly expands the types of projects allowed in Kansas Rural Housing Incentive Districts (RHID) and enables the renovation into residential use (including vertical construction) of buildings and structures more than 25 years old on Kansas main streets and downtown districts. Any city with a population of less than 60,000 will be eligible for this program, regardless of county population. This program is essential in addressing housing shortages in rural Kansas in particular.

SB 124 – The STAR Bonds program in Kansas has been continued with major updates. This legislation establishes third-party feasibility studies to be engaged by Commerce, community engagement summary requirements, and other transparency measures. Updates also include measures to increase use of the program in rural areas. Finally, the program can now be used as a tool to recruit headquarters and major business facilities with the potential to attract sizable out-of-state visitation.

“Governor Kelly is known for her unwavering support of education, but measures like these prove she is also the Economic Development Governor,” Lieutenant Governor and Commerce Secretary David Toland said. “The Governor and our partners in the Legislature are responding to the needs of businesses and communities throughout our state, making rapid growth attainable in communities of all sizes. The pillars of our Framework for Growth, including forward-thinking policy, emphasis on talent and innovation and effective leveraging of community assets all are represented in this legislation. These new laws will be truly instrumental drivers of Kansas’ economic growth.”

This announcement comes during Governor Kelly’s “Back to School, Back to Work” tour through Kansas. April 12 through April 16 is “Economic Development Week,” with Governor Kelly and Lt. Governor/Secretary Toland visiting businesses and workforce centers across the state.

To learn more about the Kansas Framework for Growth, Kansas’ economic development North Star, click here.

Additional bills Governor Kelly signed:

HB 2178: Vacating certain blocks in the original town plat set aside for a college and a park in the city of Americus and vesting fee simple title in the city.

HB 2238: Eliminating the dollar limitation for acceptance of gifts by donors to school districts or cities, or both, for library purposes.

HB 2295: Exempting municipal motor grader vehicle operators from Kansas uniform commercial drivers’ license act requirements.

COVID-19, Government

COVID 19 Brazilian Variant Identified in Sedgwick County

Leave a comment

 

TOPEKA – A Centers for Disease Control and Prevention (CDC) Emerging Variant known as the Brazilian or P.1 variant has been identified in an individual in Sedgwick County. A case investigation is being conducted to determine how the person became infected with this particular variant of the SARS-CoV-2 virus, as well as, if others may have been exposed. No further details will be released concerning the patient, including demographics.

The variant was determined through the whole genome sequencing conducted through the laboratories at the Kansas Department of Health and Environment (KDHE).

The P.1 variant was originally identified in four travelers from Brazil, who were tested during routine screening at Haneda airport outside Tokyo, Japan. This variant was detected in the U.S. at the end of January 2021 and has been found in 31 states and territories in the U.S. At this point, there is still much to learn about the transmission characteristics and potential severity of the P.1 variant. Although this strain can reduce the effectiveness of some vaccines, vaccines still provide strong protection against severe illness and death.

“We continue to encourage people to take the appropriate precautions. This includes wearing a mask that fits snuggly around the nose and face and has multiple layers of fabric or layering thinner masks with an additional cloth face mask to improve the fit,” Dr. Lee Norman, KDHE Secretary, said. “Kansans should also follow isolation and quarantine recommendations, practice physical distancing, good hygiene, staying home if ill and getting the vaccine if you are able to.”

Two other variants of concern have been identified in Kansas, including the UK variant, B.1.1.7, and the South African variant, B.1.351. Variant information in Kansas can be found on the COVID-19 dashboard under the “Variants” tab.

“In addition to following these healthy behaviors, this finding also shows the importance of getting tested for COVID-19,” Adrienne Byrne, Sedgwick County Health Director, adds.

Testing is available and free for all Kansans. To find a location near you, visit: www.coronavirus.kdheks.gov/280/COVID-19-Testing.

COVID-19, Government, Kansas

Kansas Pauses Johnson & Johnson Administration

Leave a comment

 

TOPEKA – The Kansas Department of Health and Environment (KDHE) announces that Kansas will pause administration of the Johnson & Johnson (Janssen) COVID-19 vaccine following an announcement from the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) this morning. There are reports of six recipients in the United States who developed a rare disorder involving blood clots within about two weeks of vaccination. No known cases have been reported in Kansas to date.

“Just as important as getting vaccines into arms — is making sure those vaccines are safe,” Governor Laura Kelly said. “While this appears to have affected six people in the nearly seven million doses administered, out of an abundance of caution, Kansas will suspend Johnson and Johnson until the CDC and FDA clear it for use again. In the meantime, we anticipate our shipments of Pfizer and Moderna to continue and we will build on the one-third of Kansans who have already received their first dose of the COVID-19 vaccine.”

The federal government will further study links between the vaccine and the rare blood clotting disorder. An emergency meeting of the CDC’s advisory committee has been scheduled for Wednesday.

KDHE asks providers with Johnson & Johnson vaccine to pause administration of the vaccine immediately and to place the supply into storage while material is reviewed. After KDHE has reviewed the findings from the federal government, further guidance will be given to providers on next steps.

Those who have received the Johnson & Johnson vaccine should contact their health care provider if they have any symptoms and report any illness to the VAERS Reporting System, https://vaers.hhs.gov.

The week of April 19th, Kansas is anticipated to receive the following doses:

  • 39,780 Pfizer Prime
  • 38,610 Pfizer Boost
  • 29,000 Moderna Prime
  • 27,800 Moderna Boost

Joint CDC and FDA Statement

As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.

CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.

Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.htmlexternal icon.

CDC and FDA will provide additional information and answer questions later today at a media briefing. A recording of that media call will be available on the FDA’s YouTube channel.

###

COVID-19, Government, Kansas

KDHE amends travel quarantine list

Leave a comment

 

TOPEKA – The Kansas Department of Health and Environment (KDHE) has amended its travel quarantine list to add several states and countries – Connecticut and Pennsylvania and the countries of Andorra, Bermuda, Curacao, Poland, Serbia and Uruguay. Two countries, Czechia and Montenegro are removed.

A comprehensive list of those individuals needing to quarantine includes visitors and Kansans who have:

  • Traveled on or after April 8 to Connecticut or Pennsylvania
  • Traveled on or after April 8 to Andorra, Bermuda, Curacao, Poland, Serbia or Uruguay
  • Traveled on or after March 26 to Delaware, Michigan or Rhode Island
  • Traveled on or after March 26 to Hungary or Jordan
  • Traveled on or after March 12 to New Jersey or New York
  • Traveled on or after March 12 to State of Palestine or Estonia
  • Traveled on or after Feb. 26 to San Marino
  • Traveled between Feb. 26 – April 8 to Czechia or Montenegro.
  • Attendance at any out-of-state mass gatherings of 500 or more where individuals do not socially distance (6 feet) and wear a mask.
  • Been on a cruise ship or river cruise on or after March 15, 2020.

The travel quarantine period is seven days with a negative test result or 10 days without testing, with release from quarantine on Day 8 and Day 11, respectively. Further information on quarantine periods can be found on KDHE’s website.

For those traveling internationally, the Centers for Disease Control and Prevention (CDC) is requiring testing within three days of flights into the U.S. For further information on this and other requirements, visit their website.

For those who are fully vaccinated (meaning it has been greater than two weeks since they completed their vaccinations) they are not required to quarantine regarding travel if they meet all of the following criteria:

  • Are fully vaccinated (i.e., ≥2 weeks following receipt of the second dose in a 2- dose series, or ≥2 weeks following receipt of one dose of a single-dose vaccine)
  • Are within 6 months following receipt of the last dose in the series
  • Have remained asymptomatic since the travel

Persons who do not meet all three of the above criteria should continue to follow current quarantine guidance for travel.

Additionally, people with previous COVID-19 disease are not required to quarantine following travel if they meet all of the following criteria:

  • Have evidence of a previous infection supported by a positive PCR or antigen test
  • Are within 6 months following infection. If an investigation was done documenting the date that symptoms resolved, or the date isolation measures were discontinued for asymptomatic patients, then the 6-month period can start from that end date. If those dates are not available, then the period will start from the date of the positive laboratory test. A serology or antibody test may not be substituted for a laboratory report of a viral diagnostic test.
  • Have remained asymptomatic since the travel

Persons who do not meet all three of the above criteria should continue to follow current quarantine guidance for travel.

The travel quarantine list is determined using a formula to evaluate new cases over a two-week period, then adjusted for population size to provide a case rate per 100,000 population. This provides a number that can then be compared to the rate in Kansas. Locations with significantly higher rates — approximately 3x higher — are added to the list.

For more information on COVID-19, please visit the KDHE website at www.kdhe.ks.gov/coronavirus.

Community Health Center of Southeast Kansas, COVID-19

Johnson & Johnson vaccine available at all CHC/SEK clinics by appointment  

Leave a comment
The one-dose Johnson & Johnson COVID-19 vaccine is now available and at all Community Health Center of Southeast Kansas locations.
Currently, the vaccine is recommended for people age 18 and older. The Johnson & Johnson vaccine offers two unique advantages. It is a single dose rather than the currently required two doses for Pfizer and Moderna. The single dose requires less of a time commitment and inconvenience than a two-dose regimen, and also eliminates the logistical difficulties of scheduling second doses.
To schedule a Johnson & Johnson COVID-19 vaccine, go to the website chcsek.org, click the COVID Vaccination Form button and complete the form. After selecting the “first dose” button, there is an option to select Johnson & Johnson or Moderna. CHC/SEK representatives will contact the recipients to schedule a date for the vaccine.
For those without web access, the health center has a toll-free number, 866-888-8650 and a second number for Spanish-speakers 620-240-8940 to make vaccination appointments.
Various CHC/SEK Johnson & Johnson pop-up clinics will also be posted on the CHC/SEK Facebook page.

As with all COVID-19 vaccines, there is no out-of-pocket costs to vaccine recipients.